Disc Medicine
IRON
112 hedge funds and large institutions have $1.17B invested in Disc Medicine in 2023 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 41 increasing their positions, 28 reducing their positions, and 10 closing their positions.
220% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 10
46% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 28
30% more call options, than puts
Call options by funds: $12.4M | Put options by funds: $9.58M
26% more capital invested
Capital invested by funds: $934M → $1.17B (+$239M)
23% more funds holding
Funds holding: 91 → 112 (+21)
2.76% less ownership
Funds ownership: 86.89% → 84.13% (-2.8%)
25% less funds holding in top 10
Funds holding in top 10: 8 → 6 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
+$57M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
+$18.1M |
| 3 |
BlackRock
New York
|
+$11.5M |
| 4 |
Pictet Asset Management
Carouge,
Switzerland
|
+$9.99M |
| 5 |
Morgan Stanley
New York
|
+$8.97M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$51.2M |
| 2 |
O
OrbiMed
New York
|
-$29.1M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$28.6M |
| 4 |
AVLSA
Atlas Venture Life Science Advisors
Cambridge,
Massachusetts
|
-$9.74M |
| 5 |
5VM
5AM Venture Management
San Francisco,
California
|
-$7.38M |
IRON Hedge Fund Activity: Q4 2023 in Review
112 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Disc Medicine (IRON) for Q4 2023, worth a combined $1.17B — up 26% from $934M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new IRON positions and 10 closed out — a net gain of 22 holders — while 41 added to existing stakes and 28 trimmed.
The largest buyer was Paradigm Biocapital Advisors, adding an estimated $57M. The largest seller was Novo Holdings A/S, exiting entirely with an estimated $51.2M sold.
- 112 institutional investors held Disc Medicine (IRON) as of Q4 2023, up from 91 in Q3 2023.
- Funds reported $1.17B of Disc Medicine stock for Q4 2023, up 26% quarter-over-quarter.
- 32 funds opened new Disc Medicine positions in Q4 2023 and 10 closed out, a net change of +22 holders.
- The largest Disc Medicine buyer in Q4 2023 was Paradigm Biocapital Advisors, an estimated $57M added.
- The largest Disc Medicine seller in Q4 2023 was Novo Holdings A/S, an estimated $51.2M sold.
Based on aggregated 13F filings for Q4 2023.